(Total Views: 680)
Posted On: 05/23/2024 6:07:43 AM
Post# of 148870
Compare sp potential --- something I rarely do, but LL is a rarity.
Nvidia:
2.5b shares
$1k per share
Sells chips.
Market competitors, who seems like weekly/monthly, announce advancements.
Projection is 5 year market dominance.
Cytodyn:
1b shares
.24 cents
Sells extension(s) of life.
Potentially 85% of Oncology.
Controls CCR5 axis via patents.
Projection is 18.5 years of dominance. (Just oncology)
Dr. J has said goal is non-dilutive funding.
Last letter said little to no cost to Cytodyn.
Selling 500m shares @ .25 = $125m.
Enough to trial a proof of MOA.
Still having 1b shares less than an Nvidia.
40k doses on hand & every increase above .25, makes for a very big difference. Not to mention Mitch won't need to raise the whole "$125m", @ once either.
Cytodyn is not financially backed up against a wall, as the share price is alluding to.
If secure a great colecterol trial funding agreement, it lays the foundation towards proving this Nvidia comparison.
& Nvidia didn't jump to a big board or sp heights overnight either.
Cytodyn could mimic their dominance, much quicker.
As posters pointed out ---- Cytodyn only needs 1 approval & LL can be subscribed for any disease.
Posters also point out --- Colecterol has the highest CCR5 of the cancers.
LL's odds of success, should be outstanding.
Shall see...... : )
Nvidia:
2.5b shares
$1k per share
Sells chips.
Market competitors, who seems like weekly/monthly, announce advancements.
Projection is 5 year market dominance.
Cytodyn:
1b shares
.24 cents
Sells extension(s) of life.
Potentially 85% of Oncology.
Controls CCR5 axis via patents.
Projection is 18.5 years of dominance. (Just oncology)
Dr. J has said goal is non-dilutive funding.
Last letter said little to no cost to Cytodyn.
Selling 500m shares @ .25 = $125m.
Enough to trial a proof of MOA.
Still having 1b shares less than an Nvidia.
40k doses on hand & every increase above .25, makes for a very big difference. Not to mention Mitch won't need to raise the whole "$125m", @ once either.
Cytodyn is not financially backed up against a wall, as the share price is alluding to.
If secure a great colecterol trial funding agreement, it lays the foundation towards proving this Nvidia comparison.
& Nvidia didn't jump to a big board or sp heights overnight either.
Cytodyn could mimic their dominance, much quicker.
As posters pointed out ---- Cytodyn only needs 1 approval & LL can be subscribed for any disease.
Posters also point out --- Colecterol has the highest CCR5 of the cancers.
LL's odds of success, should be outstanding.
Shall see...... : )
(7)
(1)Scroll down for more posts ▼
